Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials.

Robert A Fletcher William G Herrington Rajiv Agarwal Kaitlin J Mayne Clare Arnott Meg J Jardine Kenneth W Mahaffey Vlado Perkovic Natalie Staplin David C Wheeler Glenn M Chertow Hiddo J L Heerspink Brendon L Neuen

Clin J Am Soc Nephrol

The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.

Published: April 2024

Clinical Trial registry name and registration number: ClinicalTrials.gov Identifiers: NCT02065791 (CREDENCE), NCT03036150 (DAPA-CKD), NCT03594110 (EMPA-KIDNEY).

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11390023	PMC
http://dx.doi.org/10.2215/CJN.0000000000000470	DOI Listing

Publication Analysis

Top Keywords

effects sodium-glucose

sodium-glucose cotransporter

cotransporter inhibitors

inhibitors cause-specific

cause-specific cardiovascular

cardiovascular death

death patients

patients ckd

ckd meta-analysis

meta-analysis ckd

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!